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C L I N I C A L O U T C O M E
Latex antigen testing of the cerebrospinal fluid
(CSF) and blood were positive for Cryptococcus
neoformans with a titre of 1 : 4096 and the organism
grew on Sabouraud agar. Subculture on L-lahava-
nine glycine bromothymol blue (CGB) agar
yielded blue colonies, identifying a C. neoformans
var. gattii. This yeast was found to be susceptible,
using the E test method, to amphotericin B, itra-
conazole, fluconazole and 5-flucytosine.
A diagnosis of cryptococcal meningitis was
made and a search for risk factors showed that:
human immunodeficiency virus (HIV) serology
was negative, CD4þ lymphocyte levels were nor-
mal in both percentage (30%) and absolute number
(700 cells/mL) and total haemolytic complement
levels were within normal limits. No cancers were
found, nor was there any history of use of immu-
nosuppressive drugs. A contrast-enhanced com-
puterized tomographic scan of the brain and
sinuses was unremarkable.
Fluconazole, at the dose of 1200 mg, given intra-
venously, was started but 1 week later, because of
the persistence of fever and headache, treatment
was changed to liposomal amphotericin B (5 mg/
kg/day). After 4 weeks it was changed again to
itraconazole and after 2 more weeks of treatment
the patient flew back to the USA, completely
recovered from his symptoms.
The cytokine levels (measured using enzyme-
linked immunosorbent assay) on CSF and serum at
the beginning of the disease and after 4 weeks of
antifungal therapy are reported in Table 1. A
remarkable increase of interleukin-10 (IL-10) in
the CSF was noted at the beginning of the disease,
this cytokine decreased after effective antifungal
therapy. Interferon-g (IFN-g) was never stimu-
lated during the disease.
D I A G N O S I S
The diagnosis was meningitis due to Cryptococcus
neoformans var. gattii.
D I S C U S S I O N
Cryptococcus neoformans var. gattii meningitis is
rare among immunodepressed people and affects
especially immunocompetent patients exposed to
the flowering of the Australian tree Eucalyptus
camaldulensis [1,2]. This meningitis is rare in Eur-
ope [3–5]. The patient described here had travelled
in many countries but had never travelled across
Australia. The only risk factor for this patient
appeared to be the improper and heavy use of
eucalyptus extract.
Eucalyptus extracts could contain C. neoformans
var. gattii yeasts derived from the eucalyptus trees,
but the culture of the gel used recently by the
patient was negative for bacteria and fungi. How-
ever, this finding might not exclude the possibility
that the patient was exposed to C. neoformans var.
gattii through eucalyptus extract.
In relation to cytokine levels in patients with
cryptococcosis, if we take as reference values in
CSF those found by Chaka et al. [6], we observed
that at the beginning of the disease in our patient,
there were high levels of IL-10 and tumour necro-
sis fator-a (TNF-a) and low levels of IL-1b, IFN-g
and IL-12. In the serum we observed low levels of
IL-10, IL-1b, IFN-g, IL-12, but in contrast, a mod-
erate level of TNF-a was observed. It is notable that
IL-10 was almost undetectable in the serum; this
could mean that the production of IL-10 was not
regulated by the presence of C. neoformans var.
gattii capsular antigen, because the cryptococcal
antigen latex titre was the same in the CSF and the
serum. After 4 weeks of therapy there was a reduc-
tion of the production of the anti-inflammatory
cytokine IL-10 in the CSF, but on the other hand,
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there was an increased production of the pro-
inflammatory cytokine IL-12, both in the serum
and in the CSF.
This finding led us to postulate that IL-10 is
stimulated by the yeast and suppresses the inflam-
matory response [7], but only in the CSF. In fact,
IL-10 was also almost undetectable in the serum at
the beginning of the meningitis. On the contrary,
IL-12 was produced as the fungus burden
decreased after effective therapy, counteracting
the effect of IL-10 and stimulating an immune
response. IFN-g was never stimulated either in
the CSF or the serum; and this could explain
why this meningitis had a very long evolution.
This finding agrees with those of Lortholary et al.
who found increased levels of CSF IL-10 in
patients with cryptococcosis but without HIV
infection [8]. IL-10 CSF level might be used, after
more extensive studies, as a prognostic factor in C.
neoformans var. gatti meningitis.
We started antifungal therapy with high-dose
fluconazole, but changed to liposomal amphother-
icin B due to persistent fever and headache.
Although high-dose fluconazole might be effective
from the beginning of cryptococcal meningitis [9],
there are some studies that have hypothesized that
amphotericin B may be more effective in the first
2 weeks of therapy because of its more fungicidal
effect [10].
In this patient there were none of the common
risk factors found in cryptococcal meningitis.
However, the improper use of eucalyptus extracts,
which might be a reservoir for C. neoformans var.
gattii, could be considered a risk factor for this kind
of meningitis.
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Table 1 Cryptococcal antigen titres and cytokine levels in
CSF and serum of a patient with C. neoformans var. gattii
meningitis, at the beginning of the disease and after






CSF 1 : 4096 1 : 1024
Serum 1 : 4096 1 : 1024
IL-10 (pg/mL)
CSF 146.8 35.9
Serum 0.2 0.1 <8.9
TNF-a (pg/mL)
CSF 156 160
Serum 21 18 <14
IL-1b (pg/mL)
CSF 35 29
Serum 21 23 <21
IFN-g (UI/mL)
CSF 0.7 0.5
Serum 0 0.3 <1.2
IL-12 (pg/mL)
CSF 6 16
Serum 27 60 80
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